The recent surge in funding into niche pharmaceutical companies, particularly those focusing on groundbreaking therapies and challenging drug development programs, has fueled what some are calling "High Roller Pharma." https://leaxmml605326.bloggadores.com/39055611/high-stakeholder-pharma-the-hazardous-bet